Determinants of Warfarin Metabolism
ConditionHealthy
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age20-50
SponsorHadassah Medical Organization
About this trial
The anticoagulant effect of warfarin varies greatly among individuals. Some of this variability is attributed to differences in the activity of CYP2C9, the predominant enzyme involved in the metabolism of S-warfarin.
The present study is designed to define the differences in warfarin metabolism among healthy individuals carrying different CYP2C9 genotypes. In addition, the study will define the correlation between the phenytoin metabolic ratio, a marker of CYP2C9 activity in vivo, and warfarin metabolism.
Eligibility criteria
Qualifiers
Age range of 20-50 years old
The absence of significant disease states
Disqualifiers
Known hypersensitivity to warfarin or phenytoin
Known hepersensitivity to penicillins or cephalosporins (Dicloxacillin part)
The presence of significant disease states
Regular use of drugs (including birth control pills)
Trial design
Treatments tested in this trial
- Warfarin
- Phenytoin
- Losartan & Hydrochlorothiazide
- Flurbiprofen
- Siponimod
- Dicloxacillin
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov